Recent Advances in Pharmaceutical Microbiology and Ongoing Challenges

Jeanne Moldenhauer- Excellent Pharma Consulting, Inc.

Introduction

Pharmaceutical microbiology is a rapidly evolving discipline that plays a critical role in ensuring the safety, efficacy, and quality of pharmaceutical products. The last few years have witnessed significant innovations in techniques and methods, often driven by the need for faster drug development, stricter regulatory requirements, and the emergence of new therapeutics such as biologics and personalized medicine.^1-3 This paper reviews some of the newest advances in pharmaceutical microbiology as well as some of the ongoing challenges to pharmaceutical microbiologists.

Advances

The Microbiome and Personalized Medicine

The human microbiome has been shown to play a significant role in drug metabolism, efficacy, and safety, influencing individual responses to therapy.^4-6 Advances in pharmacomicrobiomics - the study of drug microbiota interactions plays a key role in the future of personalized medicine:

• Microbiome-Based Diagnostics:  Studies are being conducted to better understand the microbiome in individuals and how that can be utilized to aid in the diagnosis and/or prevention of disease. These studies are being conducted for organisms in different systems of the body (e.g., gut, skin, and so forth). This led to microbial fingerprints being developed as non-invasive diagnostic tools for disease phenotyping and prognosis ^5,6

• Drug-Microbiota Interactions: Research shows that gut microbiota can modify drug absorption, distribution, metabolism, and excretion, impacting therapeutic outcomes and adverse drug reactions.⁶

• Precision Probiotics and Prebiotics:  Tailored interventions targeting specific microbial pathways are being explored to optimize treatment for multifactorial diseases.^5,6

These developments promise to improve patient outcomes and reduce the risk of adverse drug reactions through individualized therapy.^5,6

Biofilm Control and Innovative Antimicrobial Strategies

Biofilms, which are complex communities of microorganisms encased in a self-produced matrix, pose significant challenges in pharmaceutical manufacturing due to their resistance to antimicrobial agents and their ability to contaminate equipment and products.² Recent research has focused on:

• Novel Antimicrobial Agents: Development of antimicrobial peptides (AMPs) and bioactive molecules that can disrupt biofilm formation or disperse established biofilms, often in combination with conventional antibiotics to enhance efficacy and delay resistance.⁸ Additionally, use of ozone products in the correct concentrations can also aid in the eradication of biofilms.

• Advanced Imaging and Biomaterials: Use of new imaging techniques and surface modifications to monitor and prevent biofilm formation on pharmaceutical equipment. ⁹

• Understanding Biocide Interactions: Studies on the interplay between biocide exposure and the emergence of antimicrobial resistance within biofilms are leading to more targeted and effective disinfection. protocols ^{8, 10}

These strategies are crucial for maintaining product quality and safety in the face of increasing complexity in pharmaceutical manufacturing.^{7,8, 9, 10}

Rapid Microbial Methods (RMM)

Traditional culture-based microbiological testing methods are time-consuming, often requiring several days to yield results. The demand for faster, more accurate testing has led to the widespread adoption of rapid microbial methods (RMM), which include technologies such as polymerase chain reaction (PCR), ATP bioluminescence, next-generation sequencing (NGS), and matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry (MALDI-TOF MS).^1,2,9 These methods can deliver results within hours, enabling pharmaceutical companies to make quicker decisions, reduce time-to-market, and improve product safety ^1,2

• PCR and NGS:  Allow for high-throughput, sensitive detection and identification of microorganisms, including those that are difficult to culture.^1,2

• ATP Bioluminescence: Provides a rapid assessment of microbial contamination by detecting adenosine triphosphate, a universal energy molecule in living cells. This technology is appealing since it does not require that the cells be cultured.^1,2

• Robotic Systems for Monitoring (ATP): There has been an increase in the development of robotic systems to automatically collect and monitor, e.g., environmental monitoring and sample collections.

• Viability-Based (e.g., Staining and Scanning Systems): Technologies like the ScanRDI were among the early RMMs in the industry. Early innovations in this area were highly manual, with little to no automation. More recent technologies have adapted these types of technologies to include more automation of early processing steps and allow for additional incubation to grow out the organisms, allowing for subsequent identification of the contaminant. It will be interesting to see whether this significantly changes the market.

• MALDI-TOF MS: Offers rapid and cost-effective identification of bacteria and fungi by analyzing their unique protein fingerprints. This technology has been widely implemented in the pharmaceutical industry due to its quality, low cost, and high throughput capabilities. Additionally, recent innovations include protein characterization, glycoprotein analysis, quality control applications, polymer analysis, and the like.⁹

The adoption of RMMs is further encouraged by regulatory pressures from agencies such as the FDA and EMA, which require rigorous microbial monitoring, especially for biologics, vaccines, and cell and gene therapies. therapies ^1,2

It has been interesting to see that while companies originally were interested in viability-based technologies, due to the speed of obtaining results, many have resorted to pursuing growth-based technologies. (i.e., the technology they know versus the one that they don’t know.)

A big step forward in accepting these technologies is the current focus of the USP microbiology committee, which is proposing compendial chapters for the implementation of rapid methods for sterility testing, i.e., specific chapters for the implementation of specific systems. This substantially reduces the validation work required, making implementation easier.

Artificial Intelligence and Machine Learning in Microbiology

The integration of AI and machine learning has revolutionized pharmaceutical microbiology by enabling faster, more accurate microbial detection and data analysis.¹¹ AI-driven technologies are now used to automate routine testing tasks, reduce human error, and optimize laboratory workflows ¹¹

• Predictive Analytics: AI models can forecast contamination risks and enable proactive interventions, which are particularly important in the production of biologics and other sensitive products.

• Antimicrobial Resistance (AMR) Prediction: Machine learning algorithms analyze large genomic datasets to predict resistance patterns, aiding in the selection of effective therapies and reducing the spread of resistant strains.⁷

• Automation of Quality Control: AI tools streamline the review of PCR data, improving efficiency and ensuring rigorous quality standards in microbiology  laboratories ¹¹

These advances not only enhance the speed and accuracy of testing but also support regulatory compliance and cost-effective manufacturing.¹¹

On-Going Concerns

Regulatory and Data Integrity Trends

With the increasing adoption of advanced technologies, regulatory agencies have placed greater emphasis on data integrity, traceability, and compliance in pharmaceutical microbiology.² The implementation of validated analytical methods and robust documentation practices is essential to ensure the reliability of microbiological data and to meet evolving regulatory standards.² This has been difficult for microbiologists as some of the “data integrity” issues are not easily resolved without advancement to more automated microbiological processes, e.g., do all plates need to be counted by multiple people to have integral data.

Reactionary versus Prevention

An ongoing concern is the “firefighter reaction” mode of pharmaceutical microbiological rather than the implementation of preventative measures. Changes are often made to corrective measures, rather than the implementation of preventative measures. For example, antimicrobial and/or antifungal filters, paints, and coatings have been in existence for many years, and they significantly reduce the likelihood of contamination, but are not widely used. We need to change our mindset to prevention.

Staffing

It continues to remain difficult to recruit and maintain pharmaceutical microbiologists. Unfortunately, an academic degree in microbiology does not adequately prepare an individual to work in pharmaceuticals. Training them takes time. Once they are trained, it can be easy to lose them to other companies. It may also be difficult to find individuals with the desired skill sets in addition to microbiology, e.g., a chemistry background, experience with artificial intelligence, and computer skills. There are also fears of being replaced by artificial intelligence or automation.¹²

Changes in Compendial Requirements

Compendial requirements set the standards for how methods are deemed acceptable, e.g., if there is a question on the data recovered and there is a compendial method, the compendial method is the referee, i.e., the deciding method. Unfortunately, many of these methods are hundreds of years old. Unfortunately, not all the methods used in the laboratory are compendial, and in this case, the site’s validation of the method would be used to “confirm” the data.¹²

With the advancement of rapid microbiological methods, which are not growth-based, setting specific limits for viability-based methods, which may not count traditional colonies, can be difficult. On the good news side, the current USP Microbiology Committee is proposing new chapters for RMMs, which would significantly reduce the time necessary to implement the methods and set limits for the test.

Regulatory Compliance

Changing to new or updated methods may result in the need for changes to regulatory filings. This can be costly and significantly delay implementation of the new and/or better methods. Having a regulatory department that is familiar with all the ways to submit changes may significantly reduce this challenge, e.g., use of comparability protocols to preapprove the validation and expectations for implementation.

Differences between Chemistry and Microbiology

When requesting money for new equipment, there is a management expectation that a cost of $70,000 or more for a piece of chemistry equipment is the norm. However, if the equipment is for the microbiology department, there typically is not the same expectation. One of the more recent additions to microbiology laboratories has been the use of Maldi-TOF, which is expensive but offers great throughput and significant cost avoidance.

Automation is coming to microbiology methods, but one needs to correlate this information to the results obtained by compendial and/ or traditional methods. We also need to look at the new potential risks associated with the method, e.g., failure mode analysis.¹²

For example, there are robotic systems available that can collect environmental monitoring samples and data, but there are no current guidelines for how these systems can be implemented.¹²

Knowledge Management, Data and Artificial Intelligence Systems

Tidswell indicates that “the breadth and depth of knowledge associated with microbiology and pharmaceutical microbiology is growing exponentially and will continue to.” He also highlights the “growing pains” associated with the copious amounts of literature and data available, and trying to review, know, and use this information. ¹²

Conclusion

Pharmaceutical microbiology is undergoing a period of major innovation, driven by alternative and/or rapid microbial methods, AI and machine learning, advanced biofilm control strategies, and the integration of microbiome science into drug development.^1,2 These advances can improve the speed, accuracy, and cost-effectiveness of microbial testing, supporting the development of safer and more effective pharmaceutical products. As the field continues to evolve, ongoing research and collaboration between microbiologists, data scientists, and regulatory authorities will be essential to address emerging challenges and harness the full potential of these transformative technologies. technologies technologies ^2,6,12

Despite all these advances, many other characteristics of pharmaceutical microbiology continue to be challenging, e.g., continuing to react in response to deviations and problems rather than prevention of the same, obtaining and keeping qualified microbiologists, changing regulatory requirements, and differing expectations and requirements for chemistry and microbiology departments.

References

1. Grand View Research. “Pharmaceutical Rapid Microbiology Testing Market Report 2030.” Accessed June 17, 2025. https://www.grandviewresearch.com/industry-analysis/ pharmaceutical-rapid-microbiology-testing-market-report.
2. Pharma Connections. “Emerging Trends in Pharmaceutical Microbiology In pharma.” Accessed June 17, 2025. https://pharmaconnections.in/emerging-trends-in pharmaceutical-microbiology/.
3. Auctores Journals. “Introduction to Pharmaceutical Microbiology.” Accessed June 17, 2025. https://www.auctoresonline.org/article/introduction-to-pharmaceutical-microbiology.
4. PMC. “Proceedings of the Clinical Microbiology Open 2024: artificial ...” Accessed June 17, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11980357/.
5. Frontiers in Cellular and Infection Microbiology. “Editorial: The ever so elusive pathogen harboring biofilms on abiotic ...” Accessed June 17, 2025. https://www.frontiersin.org/ journals/cellular-and-infection-microbiology/articles/10.3389/. fcimb 2024.1374693/full.
6. Nature. “Drug-microbiota interactions: an emerging priority for precision ...” Accessed June 17, 2025. https://www.nature.com/articles/s41392-023-01619-w.
7. Kumari, Mamta et al. “Microbial Biofilms in Pharmaceuticals: Challenges, Mechanisms, and Innovative Solutions.” Accessed June 17, 2025. https://eijppr.com/storage/ files/article/556a4ba0-37da-460f-a415-b160a128018f-jn8FMUIvQ23AHze0/ paco5z9TSWGPSmN.pdf.
8. PMC. “Microbiome at the Frontier of Personalized Medicine.” Accessed June 17, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC5730337/.
9. LinkedIn. “Pharmaceutical Microbiology Testing Market: Key Trends, Growth ...” Accessed June 17, 2025. https://www.linkedin.com/pulse/pharmaceutical-microbiology-testing market-qdocf.
10. American Pharmaceutical Review. “Microbiology Roundtable - American Pharmaceutical Review.” Accessed June 17, 2025. https://www.americanpharmaceuticalreview.com/ Featured-Articles/614438-Microbiology/.
11. International Journal of Medical Research. “Artificial intelligence (AI) and medical microbiology: A narrative review.” Accessed June 17, 2025. https://www.ijmronline.org/ html-article/22879.
12. Tidswell, E. (2023). Challenges in Pharmaceutical Microbiology. European Pharmaceutical Review. Downloaded from: Challenges in pharmaceutical microbiology: looking to the future

Subscribe to our e-Newsletters.
Stay up to date with the latest news, articles, and events. Plus, get special
Offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!